An alarming rise in number of ovarian cancer cases reported in the recent past, inadvertently creates a highly conducive environment for growth of the ovarian cancer drugs market. According to estimates released by the American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. The Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data stats that there in an increase in all new cancer cases, with ovarian cancer accounting for 1.3% of incidence rate, and accounting for 2.4% of all related deaths in the 2016. The number of new ovarian cancer cases are 11.9 per 100,000 women each year and the total deaths are 7.5 per 100,000 women yearly.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/164
According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 is 14.2 and 14.0, respectively. The U.K stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in less developed countries, with the least incidence rate in Africa and Asia. In the U.K., around 46% of women diagnosed with ovarian cancer, survive their disease for the following five years or more. According to Australian Government, Cancer Australia, it is estimated that in 2017, there would be 1,580 new ovarian cancer cases, with an estimated 2.5% ovarian cancer cases among all new cancer cases in the country. This would result in an estimated 1,047 deaths in 2017. Thus, the ovarian cancer drugs industry is expected to gain significant traction in the more developed regions over the following few years.
Ovarian cancer is one of the most dreadful cancers among all different cancers in females. Cancer which is grown in an ovary, results in abnormal cells growth that have the tendency to invade or adversely affect the other parts of the body.Only a few vague symptoms show up in the initial stages. Further symptoms manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite. As this is an ovarian cancer, the cancer can spread to adjoining areas such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver.
The disease is relatively rare, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. Around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in the breast cancer genes have a 50% chance of developing the disease. The most common ovarian cancer that accounts for 95% of cases, is ovarian carcinoma.
Ovarian cancer drugs market taxonomy
The global ovarian cancer drugs market is segmented on the basis of chemotherapy drugs, end user, and geography. On the basis of chemotherapy drugs, the ovarian cancer drugs are divided into Carbloplastin, Cisplatin, Docetaxel, Paclitaxel and other medication includes Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin and Topotecan.
On the basis of end user, the market is classified into hospitals, ambulatory surgical centers, clinics, and others.
Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.
Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada. According to American Cancer Society, an estimated 22,440 women would receive a new diagnosis of ovarian cancer and around 14,080 women will die from ovarian cancer in 2017 in the U.S. alone. Ovarian cancer is the fifth most prevalent cancer among women, which accounts for high percentage of deaths when compared to other cancer related to reproductive system cancer. It is stated that 1 in 75 women are at risk of contracting ovarian cancer and fatalities related to the disease is pegged at 1 in 100. Prevalence of ovarian cancer is usually low among women under 40 years of age. According to American Cancer Society, most of the ovarian cancer case are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the U.K., of which around 53% of cases diagnosed were among females aged 65 years and above.
Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/164
Combinational drug approach a novel approach in the ovarian cancer drugs market
Key players operating the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer. Introduction of such drugs would further fuel growth of the ovarian cancer drugs industry in the near future.